Re: Sanofi
That would be the Oxford AstraZeneca vaccine developed and trialled by Oxford University with UK government support with AZ being brought in only later to produce it at scale - and not-for-profit at Oxford's insistence. UK vaccine funding per head is seven times higher than the EU's (and where do you think the EU gets its money from anyway, if not member states?).
The reality is AZ chose to produce with partners located in the territory the vaccine was intended for specifically to avoid territorial spats like this and that vaccines produced in a certain territory are exclusive to that territory until a certain production number has been reached and only beyond which they can be exported. The EU Commission have twisted that last part with their agreement with AZ that UK soil could be treated as EU for the purposes of new EU production (sensible: it was invented here) and conflated it into a claim on existing UK production which is simply not in the contract.
Vaccine production is a biochemical process whose yield takes time to establish. The embarrassing truth is that the UK were around one month ahead of some EU member states in establishing AZ vaccine production, perhaps because it was developed here, up until the Commission got involved and insisted it negotiate on behalf of all of the bloc which added an additional two months, hence the three months late accusation. This is an existential embarrassment to the Commission as it suggest that when they get involved it adds little except delay and that member states are often better off acting independently as the UK has done and could only do because of? Brexit…
The Commission's response is pure face-saving and we've all had enough of that after Wuhan, Hubei and the CCP and additionally it's a distraction for AZ's CEO who has a more important task of running a corporation producing an effective, not-for-profit vaccine suitable for both developed and developing countries.
Here's some quotes from him in a Repubblica interview:
"In the EU agreement it is mentioned that the manufacturing sites in the UK were an option for Europe, but only later"
"As soon as we have reached a sufficient number of vaccinations in the UK, we will be able to use that site to help Europe as well. But the contract with the UK was signed first and the UK, of course, said 'you supply us first'"
Source: Pascal Soriot La Repubblica interview